99 related articles for article (PubMed ID: 23485467)
21. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
22. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
23. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
Ogasawara S; Kaneko MK; Tsujimoto Y; Liu X; Kato Y
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):377-81. PubMed ID: 24328739
[TBL] [Abstract][Full Text] [Related]
24. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
[TBL] [Abstract][Full Text] [Related]
25. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
26. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
[TBL] [Abstract][Full Text] [Related]
27. A vaccine targeting mutant IDH1 induces antitumour immunity.
Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M
Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048
[TBL] [Abstract][Full Text] [Related]
28. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
29. R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
Kawakami S; Ochiai K; Azakami D; Kato Y; Michishita M; Morimatsu M; Ishiguro-Oonuma T; Onozawa E; Watanabe M; Omi T
Vet Res Commun; 2018 Mar; 42(1):49-56. PubMed ID: 29285579
[TBL] [Abstract][Full Text] [Related]
30. Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.
Ogasawara S; Fujii Y; Kaneko MK; Oki H; Sabit H; Nakada M; Suzuki H; Ichimura K; Komori T; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Oct; 35(5):254-258. PubMed ID: 27788029
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
Takano S; Kato Y; Yamamoto T; Liu X; Ishikawa E; Kaneko MK; Ogasawara S; Matsuda M; Noguchi M; Matsumura A
Brain Tumor Pathol; 2015 Jul; 32(3):169-75. PubMed ID: 25652153
[TBL] [Abstract][Full Text] [Related]
32. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
Gao Y; de Wit M; Struys EA; van der Linde HCZ; Salomons GS; Lamfers MLM; Willemsen R; Sillevis Smitt PAE; French PJ
PLoS One; 2018; 13(6):e0199737. PubMed ID: 29953513
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
34. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
35. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.
Bralten LB; Kloosterhof NK; Balvers R; Sacchetti A; Lapre L; Lamfers M; Leenstra S; de Jonge H; Kros JM; Jansen EE; Struys EA; Jakobs C; Salomons GS; Diks SH; Peppelenbosch M; Kremer A; Hoogenraad CC; Smitt PA; French PJ
Ann Neurol; 2011 Mar; 69(3):455-63. PubMed ID: 21446021
[TBL] [Abstract][Full Text] [Related]
36. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
[TBL] [Abstract][Full Text] [Related]
37. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
38. Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.
Stoczynska-Fidelus E; Och W; Rieske P; Bienkowski M; Banaszczyk M; Winiecka-Klimek M; Zieba J; Janik K; Rosiak K; Treda C; Stawski R; Radomiak-Zaluska A; Piaskowski S
Anticancer Res; 2014 Jun; 34(6):2859-67. PubMed ID: 24922649
[TBL] [Abstract][Full Text] [Related]
39. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
40. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
